Overview

• The Series D round brings total funding to $275 million, with new investors including Morgan Health, Humana, Texas Oncology and Memorial Hermann alongside existing backers such as CVS Health Ventures, Foresite Capital and a16z Bio + Health.
• Thyme Care reports reaching profitability, managing more than $5 billion in oncology spend and expanding access to roughly 8 million people through new Medicare, commercial and employer contracts.
• The company partners with health plans, employers and risk-bearing providers and collaborates with more than 1,000 oncologists to build integrated, value-based oncology infrastructure.
• An AI orchestration layer aims to automate documentation, surface real-time insights and reduce administrative workload, with one partner practice cited as saving nearly 2,000 staff hours in a year.
• Company-reported results include high patient engagement and experience, with about 72% completing ePRO surveys, a 40% lower likelihood of ER visits, 19% fewer hospital admissions and roughly 90% of members feeling more supported.